Search results for "adenine"

showing 10 items of 138 documents

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma : results From the Open-Label, Multicenter, Phase II DAWN Study

2018

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee–assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classFollicular lymphomaPhases of clinical researchTyrosine-kinase inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesRecurrenceT-Lymphocyte SubsetsChemoimmunotherapyInternal medicineBiomarkers TumormedicineHumansLymphoma FollicularProtein Kinase InhibitorsAgedAged 80 and overManchester Cancer Research Centrebusiness.industryResearchInstitutes_Networks_Beacons/mcrcAdenineMiddle Agedmedicine.diseaseLymphomaPyrimidinesTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisIbrutinibPyrazolesFemaleRefractory Follicular LymphomabusinessProgressive disease030215 immunology
researchProduct

Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholes…

2001

Abstract Cholesteryl ester transfer protein (CETP) facilitates the exchange of triglycerides (TG) and cholesteryl ester between lipoprotein particles. Subjects with familial hypercholesterolemia (FH) have been reported to have higher CETP activities, which could contribute to the lower high-density lipoprotein-cholesterol (HDL-C) levels and increased cardiovascular risk observed in some of these patients. Several polymorphisms have been reported in the CETP locus; the common TaqlB polymorphism is associated, in normolipidemic subjects, with decreased CETP activity and levels and with increased HDL-C levels. No data is available on the influence of this polymorphism in FH subjects. We have e…

AdultMaleSite-Specific DNA-Methyltransferase (Adenine-Specific)medicine.medical_specialtyGenotypeApolipoprotein BLipoproteinsEndocrinology Diabetes and MetabolismPopulationFamilial hypercholesterolemiaHyperlipoproteinemia Type IIchemistry.chemical_compoundEndocrinologyInternal medicineCholesterylester transfer proteinmedicineHumanseducationNational Cholesterol Education ProgramAllelesGlycoproteinseducation.field_of_studyPolymorphism Geneticbiologymedicine.diagnostic_testmedicine.diseaseCholesterol Ester Transfer ProteinsCholesterolEndocrinologychemistryCardiovascular DiseasesSpainbiology.proteinCholesteryl esterFemalelipids (amino acids peptides and proteins)Carrier ProteinsLipid profileLipoproteinMetabolism
researchProduct

Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues

2010

Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log(10) copies/mL at the start and a minimum, period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 +/- 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of…

AdultMalemedicine.medical_specialtyHBsAgAdolescentOrganophosphonatesPharmacologyBiologymedicine.disease_causeGastroenterologyCohort StudiesSDG 3 - Good Health and Well-beingInternal medicineDrug Resistance ViralmedicineAdefovirHumansHepatitis B e AntigensTenofovirRetrospective StudiesHepatitis B virusHepatitis B Surface AntigensHepatologyReverse-transcriptase inhibitorAdenineLamivudinevirus diseasesEntecavirHepatitis BMiddle Agedmedicine.diseaseHepatitis BTreatment OutcomeHBeAgLamivudineFemalemedicine.drugHepatology
researchProduct

Current practice of chronic hepatitis B treatment in Southern Italy

2012

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (…

AdultMalemedicine.medical_specialtyHBsAgGuanineCirrhosisOrganophosphonatesPyrimidinonesNucleosides analoguesAntiviral AgentsPolyethylene GlycolsYoung AdultHepatitis B ChronicChronic hepatitisInterferonPegylated interferonInternal medicineHBVInternal MedicinemedicineHumansHepatitis B e AntigensPractice Patterns Physicians'TenofovirProspective cohort studyAgedAged 80 and overTelbivudinebusiness.industryAdenineAge FactorsInterferon-alphaNucleosidesMiddle AgedHBV; Interferon; Nucleosides analogues; Nucleotides analoguesNucleotides analoguesmedicine.diseaseRecombinant ProteinsItalyLamivudineCurrent practiceImmunologyInterferonFemalePreviously treatedbusinessThymidinemedicine.drugEuropean Journal of Internal Medicine
researchProduct

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transp…

2019

Abstract Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. The survey performed in 2009 contained 20 questions on first-line treatment and related issues and 4 questions on second-line scenarios followed by a survey on all systemic and topic treatment options known and applied, with 31 of 36 transplant centers (86%) responding. The survey in 2018 repeate…

AdultMalemedicine.medical_specialtyRuxolitinibMedizinBronchiolitis obliteransGraft vs Host DiseaseDiseasechemistry.chemical_compoundPiperidinesGermanyNitrilesmedicineHumansIntensive care medicineBronchiolitis ObliteransImmunosuppressive treatmentImmunosuppression TherapyTransplantationbusiness.industryAdenineHematopoietic Stem Cell TransplantationHematologymedicine.diseaseClinical trialGraft-versus-host diseasePyrimidineschemistryIbrutinibAustriaChronic DiseasePyrazolesFemaleAllogeneic hematopoietic stem cell transplantbusinessSwitzerlandmedicine.drugBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
researchProduct

Photobleaching effects onin vivoskin autofluorescence lifetime

2015

The autofluorescence lifetime of healthy human skin was measured using excitation provided by a picosecond diode laser operating at a wavelength of 405 nm and with fluorescence emission collected at 475 and 560 nm. In addition, spectral and temporal responses of healthy human skin and intradermal nevus in the spectral range 460 to 610 nm were studied before and after photobleaching. A decrease in the autofluorescences lifetimes changes was observed after photobleaching of human skin. A three-exponential model was used to fit the signals, and under this model, the most significant photoinduced changes were observed for the slowest lifetime component in healthy skin at the spectral range 520 …

AdultTime FactorsMaterials scienceLightPhotochemistryBiomedical EngineeringHuman skinAbsorption (skin)LipofuscinBiomaterialsNuclear magnetic resonanceFlavinsIntradermal NevusmedicineHumansNevusskin and connective tissue diseasesPhospholipidsSkinInflammationPhotobleachingbusiness.industryEquipment DesignMiddle AgedHandmedicine.diseasePhotobleachingFluorescenceAtomic and Molecular Physics and OpticsElectronic Optical and Magnetic MaterialsAutofluorescenceSpectrometry FluorescenceOxyhemoglobinsPicosecondFlavin-Adenine DinucleotideNevus IntradermalOptoelectronicsbusinessJournal of Biomedical Optics
researchProduct

Involvement of purinergic nerves in the NANC inhibitory junction potentials in pigeon oesophageal smooth muscle.

2004

1. Electrical field stimulation (EFS) (0.5 ms in train of 2-32 Hz for 300 ms) in smooth muscle of pigeon oesophagus, in the presence of atropine (1 microm) and guanethidine (1 microm), elicited an inhibitory response consisting of a transient hyperpolarization (inhibitory junction potential, IJP) associated with muscle relaxation. 2. Sodium nitroprusside (SNP, 100 microm) induced hyperpolarization correlated to mechanical relaxation. 3. The nitric oxide (NO) synthase inhibitor N(omega)-nitro-l-arginine (from 0.1 to 100 microm) caused a concentration-dependent reduction of electromechanical response to EFS indicating a role for NO in this response. 4. Apamin (1 microm) reduced both IJP and r…

AtropineGuanethidineAdenosinePatch-Clamp TechniquesNeuromuscular JunctionMuscarinic AntagonistsPharmacologyIn Vitro TechniquesInhibitory postsynaptic potentialApaminAutonomic Nervous Systemchemistry.chemical_compoundAdrenergic AgentsEsophaguspigeon oesophageal smooth muscle NANC pathways electrical field stimulation IJPAdenine nucleotidemedicineAnimalsColumbidaePharmacologyAdenine NucleotidesPurinergic receptorMuscle SmoothHyperpolarization (biology)AdenosineElectric StimulationElectrophysiologyMuscle relaxationchemistryBiochemistryApaminPurinesmedicine.symptommedicine.drugMuscle contractionMuscle ContractionAutonomicautacoid pharmacology
researchProduct

Fasting prior to transient cerebral ischemia reduces delayed neuronal necrosis.

1990

A transient brain ischemia of 30-min duration was induced by the four-vessel occlusion technique in normally fed and in 48-hr-fasted rats. Evaluation of brain damage 72 hr after ischemia showed that fasting reduced neuronal necrosis in the striatum, the neocortex, and the lateral part of the CA1 sector of hippocampus. Signs of status spongiosis in the pars reticulata of the substantia nigra were seen in 75% of fed rats and in only 19% of fasted rats. The protective effect was associated with reduction in mortality and in postischemic seizure incidence. The metabolic changes induced by fasting were evaluated before and during ischemia. After 30 min of four-vessel occlusion, fasted rats showe…

Blood GlucoseMalemedicine.medical_specialtyIschemiaHydroxybutyratesSubstantia nigraBlood PressureBrain damageBiochemistryBrain ischemiaCellular and Molecular Neurosciencechemistry.chemical_compoundNecrosisReference ValuesInternal medicinemedicineAnimalsNeuronsGlycogen3-Hydroxybutyric Acidbusiness.industryAdenine NucleotidesBrainRats Inbred StrainsFastingmedicine.diseaseRatsEndocrinologyGlucosechemistryIschemic Attack TransientOrgan SpecificityLactic acidosisAnesthesiaKetone bodiesLactatesNeurology (clinical)medicine.symptomPars reticulatabusinessEnergy MetabolismMetabolic brain disease
researchProduct

Cytomegalovirus‐specific T‐cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

2021

CD4-Positive T-LymphocytesMaleCongenital cytomegalovirus infectionCytomegalovirusT-Cell Antigen Receptor SpecificityCD8-Positive T-LymphocytesViral Matrix Proteinschemistry.chemical_compoundPiperidinesT-Lymphocyte SubsetsT cell immunitymedicineHumansIn patientViremiaProtein Kinase InhibitorsAgedAged 80 and overLymphocytic leukaemiabusiness.industryAdenineHematologyCmv dnaemiaMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellchemistryIbrutinibCytomegalovirus InfectionsDNA ViralImmunologyFemalebusinessInterferon-gamma Release TestsBritish Journal of Haematology
researchProduct